Clozapine is a very effective drug with both significant benefits and significant risks in treatment-resistant schizophrenia. Informed consent is generally accepted as both desirable and necessary in order to ensure that the patient’s human rights and dignity are respected. Disclosure is a key element of informed consent. It is unclear if the adequate documentation of disclosure is standard practice before initiation of clozapine. The aim of this study was to assess the adequacy of the documentation of disclosure in consent to clozapine treatment in an adult mental health service and to develop guidelines on disclosure. The method was a retrospective analysis of charts of patients given clozapine who received the drug through the pharmacy of a single North Dublin psychiatric hospital. Results show that current practice has evident gaps. The professional, ethical and legal issues are discussed.
- informed consent
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests: None declared.
Read the full text or download the PDF:
Other content recommended for you
- Role of primary care in supporting patients who are taking clozapine
- Delaying clozapine: how long is too long?
- Patients’ and psychiatrists’ perspectives on clozapine treatment—a scoping review protocol
- Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective
- Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study
- Study protocol for the development and internal validation of Schizophrenia Prediction of Resistance to Treatment (SPIRIT): a clinical tool for predicting risk of treatment resistance to antipsychotics in first-episode schizophrenia
- Combination of strategies to initiate clozapine for refractory schizophrenia in a patient with low neutrophil levels
- Clozapine-induced pericarditis: an ethical dilemma
- Successful rechallenge with clozapine following ‘red alert’
- Leucocytosis in clozapine-treated patients as predictor of loss of treatment response?